Control Bionics (ASX:CBL) EBIT per Share: A$-0.02 (TTM As of Dec. 2025)


What is Control Bionics EBIT per Share?

Control Bionics ASX:CBL -0.67% EBIT per Share is A$-0.02 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Control Bionics ranks better than 72.75% on this metric.

Control Bionics's EBIT per Share for the six months ended in Dec. 2025 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Control Bionics's EBIT per Share or its related term are showing as below:

ASX:CBL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 8.8   Med: 18.3   Max: 27.8
Current: 27.8

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Control Bionics was 27.80% per year. The lowest was 8.80% per year. And the median was 18.30% per year.

ASX:CBL's 3-Year EBIT Growth Rate is ranked better than
72.75% of 690 companies
in the Medical Devices & Instruments industry
Industry Median: 9.5 vs ASX:CBL: 27.80

Control Bionics's EBIT for the six months ended in Dec. 2025 was A$-3.56 Mil.

Control Bionics  (ASX:CBL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Control Bionics EBIT per Share Related Terms

Control Bionics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Control Bionics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics EBIT per Share Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial -0.05 -0.06 -0.06 -0.04 -0.02

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.01 -0.01 -0.01

Control Bionics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Control Bionics's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-6/268.677
=-0.02

Control Bionics's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.561/331.117
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of A$-0.02 mean?
Control Bionics (ASX:CBL) has a EBIT per Share of A$-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #188 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 27.2%.
Is Control Bionics' EBIT per Share too high?
Control Bionics' current EBIT per Share is A$-0.02. Based on the distribution chart, Control Bionics ranks #188 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #188 out of 690 companies for EBIT per Share. This puts Control Bionics in the upper half of its industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current EBIT per Share is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 146.7% above its estimated fair value. The current EBIT per Share is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current EBIT per Share is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.